DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer

Information source: University of Iowa
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pancreatic Neoplasms; Pancreatic Cancer

Intervention: Gemcitabine with escalating ascorbic acid (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Joseph J. Cullen

Official(s) and/or principal investigator(s):
Joseph J Cullen, MD, Principal Investigator, Affiliation: The University of Iowa
Joseph J Cullen, MD, Study Chair, Affiliation: The University of Iowa

Summary

This is a phase II study. It is designed to provide information about if high-dose ascorbate (vitamin C) increases survival for pancreatic cancer patients. The hypothesis is that vitamin C is well tolerated and increases cancer treatment effectiveness, lengthening survival time for patients with advanced pancreatic cancer.

Clinical Details

Official title: Pharmacological Ascorbate for the Control of Metastatic and Node-Positive Pancreatic Cancer (PACMAN): A Phase II Trial

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Overall survival

Secondary outcome:

Progression Free Survival

Number of drug-related adverse events per cycle

F2-isoprostane levels

Ascorbate levels

Detailed description: Adenocarcinoma of the pancreas is the fourth leading cause of cancer death in the United States and is increasing in incidence; the prognosis remains dismal. We propose to investigate an entirely new approach, using pharmacological ascorbate, combined with Gemcitabine, to treat this cancer. Intravenous ascorbate (i. e., ascorbic acid, vitamin C), but not oral ascorbate, produces high plasma concentrations, which are in the range that can be cytotoxic to tumor cells. Though ascorbate has been utilized in cancer therapy, few studies have investigated intravenous deliver of ascorbate. Preliminary studies from our group have demonstrated that ascorbate induces oxidative stress and cytotoxicity in pancreatic cancer cells; this cytotoxicity appears to be greater in tumor vs. normal cells. We hypothesize that production of H2O2 mediates the increased susceptibility of pancreatic cancer cells to ascorbate-induced metabolic oxidative stress. Gemcitabine is the standard chemotherapy drug used to treat pancreatic cancer.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients must have a cytological or histological diagnosis of adenocarcinoma arising

in the pancreas. Diagnosis from metastatic sampling is acceptable.

- Disease must be measured radiologically.

- Failed initial therapy or ineligible for definitive curative therapy.

- If prior treatment included radiation therapy, recurrent disease must be outside of

the targeted volume.

- Age ≥ 18 years

- ECOG performance status 0-2 (Karnofsky > 50%, see Appendix A).

- Patients must have normal organ and marrow function as defined below:

- leukocytes ≥ 3,000/mm3

- absolute neutrophil count ≥ 1,500/mm3

- platelets ≥ 100,000/mm3

- total bilirubin < 2x institutional upper limit of normal

- AST(SGOT) < 3x institutional upper limit of normal OR < 5x institutional upper

limit of normal for patients presenting with liver metastases

- ALT (SGPT) < 3x institutional upper limit of normal OR < 5x institutional upper

limit of normal for patients presenting with liver metastases

- PT/INR within normal institutional limits, unless patient is on warfarin

or other antithrombotic agents

- creatinine < 1. 5 X institutional upper limit of normal OR creatinine clearance ≥

60 mL/min/1. 73 m2 for patients with creatinine levels above institutional normal.

- Not pregnant. Women of child-bearing potential and men must agree to use

adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

- Ability to understand and the willingness to sign a written informed consent

document. Exclusion Criteria:

- Prior chemotherapy to treat metastatic disease.

- Adjuvant therapy (including radiation therapy) within 4 calendar weeks.

- Unresolved toxicities from prior therapy for the malignancy.

- G6PD (glucose-6-phosphate dehydrogenase) deficiency.

- Second malignancy other than non-melanoma skin cancers within the past 5 years.

- Excess consumption of alcohol where an excess of alcohol is defined as more than four

of any one of the following per day: 30 mL distilled spirits, 340 mL beer, or 120 mL wine.

- Uncontrolled intercurrent illness including, but not limited to ongoing or active

infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness/social situations, or any other condition that would limit compliance with study requirements as determined by study team members.

- Pregnant or lactating women: The risks of chemotherapy to a fetus/infant are well

documented.

Locations and Contacts

The Holden Comprehensive Cancer Center, Iowa City, Iowa 52242, United States
Additional Information

Related publications:

Cullen JJ. Ascorbate induces autophagy in pancreatic cancer. Autophagy. 2010 Apr;6(3):421-2. Epub 2010 Apr 15.

Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, Taghiyev AF, Du C, Knudson CM, Cullen JJ. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res. 2010 Jan 15;16(2):509-20. doi: 10.1158/1078-0432.CCR-09-1713. Epub 2010 Jan 12.

Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 Mar;71(3):765-75. doi: 10.1007/s00280-013-2070-8. Epub 2013 Feb 5.

Starting date: September 2012
Last updated: May 26, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017